InvestorsHub Logo
Followers 829
Posts 119620
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 1872

Friday, 07/31/2020 9:39:08 AM

Friday, July 31, 2020 9:39:08 AM

Post# of 2958
ABBV’s 2Q20 Mavyret sales=$376M, -33% QoQ, -51% YoY—the decline was attributable to fewer new-patient starts during the COVID-19 pandemic:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2020-financial-results.htm

ABBV lowered full-year-2020 Mavyret sales to $2.1B (from the prior guidance of $2.3B), which implies 2H20 Mavyret sales of $1.0-1.1B. I.e., expected Mavyret sales during 2H20 will be almost equal to the run rate in the Jan 2020 (pre-COVID-19) guidance.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News